Therapix Biosciences Ltd. (TRPX)
Stock Price:
$0.320 USD
-0.300 (-48.39%)
Updated Jul 1, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.83M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-4.58M |
| Shares Out |
5.72M |
| EPS (ttm) |
-1.28 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 1, 2020 |
| Last Price |
$0.320 |
| Previous Close |
$0.620 |
| Change ($) |
-0.300 |
| Change (%) |
-48.39% |
| Day's Open |
- |
| Day's Range |
0.301 - 0.400 |
| Day's Volume |
0 |
| 52-Week Range |
0.250 - 4.690 |
More Stats
| Market Cap |
1.83M |
| Enterprise Value |
1.11M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
5.72M |
| Float |
3.71M |
| EPS (basic) |
0.64 |
| EPS (diluted) |
-1.28 |
| FCF / Share |
-0.39 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
187,878 |
| Short Ratio |
0.05 |
| Short % of Float |
n/a |
| Beta |
0.39 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
734.59 |
| Revenue |
n/a |
| Operating Income |
-4.11M |
| Net Income |
-4.58M |
| Free Cash Flow |
-3.97M |
| Net Cash |
719,000 |
| Net Cash / Share |
0.13 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-89.87% |
| ROE |
-9,843.96% |
| ROIC |
685.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
18.0
Current: 0.320
High
18.0
Target: 18.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | - | - | - | - | - | - |
| Operating Income | -4.11 | -7.24 | -5.75 | -2.01 | -1.60 | -7.04 |
| Net Income | -4.58 | -9.38 | -6.24 | 1.99 | 2.54 | -7.21 |
| Shares Outstanding | 204 | 140 | 41.00 | 41.00 | - | - |
| Earnings Per Share | 0.64 | 1.20 | 1.00 | -1.00 | -2.20 | -9.00 |
| EPS Growth | -46.67% | 20% | - | - | - | - |
| Operating Cash Flow | -4.70 | -7.13 | -4.58 | -1.47 | -1.40 | -7.36 |
| Capital Expenditures | 0.72 | 0.03 | -0.04 | - | - | 0.22 |
| Free Cash Flow | -3.97 | -7.11 | -4.62 | -1.48 | -1.40 | -7.14 |
| Cash & Equivalents | 0.88 | 2.03 | 9.22 | 0.69 | 6.18 | 0.66 |
| Total Debt | 0.16 | 0.87 | - | - | - | - |
| Net Cash / Debt | 0.72 | 1.16 | 9.22 | 0.69 | 6.18 | 0.66 |
| Assets | 1.15 | 4.56 | 9.57 | 1.25 | 6.50 | 1.02 |
| Liabilities | 1.14 | 4.48 | 1.18 | 0.67 | 1.99 | 1.47 |
| Book Value | 0.01 | 0.19 | 8.39 | 0.57 | 5.11 | -0.14 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Therapix Biosciences Ltd. |
| Country |
Israel |
| CEO |
Gilad Bar-Lev |
Stock Information
| Ticker Symbol |
TRPX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: TRPX |
| IPO Date |
March 22, 2017 |
Description
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.